Search results for "MIB"

showing 10 items of 193 documents

Single-cell analysis of population context advances RNAi screening at multiple levels

2012

Isogenic cells in culture show strong variability, which arises from dynamic adaptations to the microenvironment of individual cells. Here we study the influence of the cell population context, which determines a single cell's microenvironment, in image‐based RNAi screens. We developed a comprehensive computational approach that employs Bayesian and multivariate methods at the single‐cell level. We applied these methods to 45 RNA interference screens of various sizes, including 7 druggable genome and 2 genome‐wide screens, analysing 17 different mammalian virus infections and four related cell physiological processes. Analysing cell‐based screens at this depth reveals widespread RNAi‐induce…

infektiosystem biologyvirussysteemibiologiainfection
researchProduct

Adjuvant intravesical therapy in intermediate risk non-muscle invasive bladder cancer (NMIBC) recurring after first cycle of intravesical treatment.

2011

Introduction and objectives The therapeutic management of intermediate risk NMI-BC recurring after intravesical therapy (IT) is not established. Cystectomy will be offered to patients at higher risk of progression but the majority will be retreated by IT. Although some Authors suggest BCG when intravesical chemotherapy (ICH) fails, some patients are retreated by ICH and some others repeat BCG adopted as first-line treatment. Not many studies have been published on this issue. The response to retreatment by intravesical therapy in terms of recurrence-free rate (RFR) and recurrence-free survival (RFS) is analyzed in 179 intermediate-risk patients. Materials and methods Only intermediate-risk …

intravesical chemotheray bladder cancer NMIBCSettore MED/24 - Urologia
researchProduct

Are Energy Market Integrations a Green Light for FDI?

2015

This paper studies the effect of energy market integration (EMI) on foreign direct investment (FDI). EMIs diminish energy uncertainty and price volatility in the host country and affect FDI through two channels: first, by harmonizing energy prices and, second, by reducing price dispersion. FDI may, as a result, increase both within and outside the EMI area, through energy stability mechanisms and price mechanisms, respectively. An empirical application on a global dataset including bilateral FDI data, during 2003-2012, using the gravity equation, shows that the integration of Portugal and Spain's electricity market in 2007 increased the amount of FDI's participants. Additionally, a positive…

jel:F20jel:F21Foreign direct investmentInternational economicsjel:F23jel:Q40Host countryEnergy stabilityjel:Q43Price dispersionEconomicsEnergy integration agreements foreign direct investment gravity equation electricity prices MIBELElectricity marketEnergy marketGravity equationVolatility (finance)SSRN Electronic Journal
researchProduct

Effect of peracetic acid on levels of geosmin, 2-methylisoborneol, and their potential producers in a recirculating aquaculture system for rearing ra…

2019

In recirculating aquaculture systems (RAS)s, off-flavors and odors, mainly caused by geosmin (GSM) and 2-methylisoborneol (MIB), can accumulate in the flesh of fish from RAS water, reducing the profitability of production. In this study, peracetic acid (PAA) was applied in three application intervals to pump sumps of rainbow trout (Oncorhynchus mykiss) reared in RAS. Using a real-time polymerase chain reaction (qPCR), the potential off-flavor producers were quantified using geoA and MIB synthase genes. Streptomyces was identified as the major GSM producer, and biofilters showed the highest number of potential off-flavor producers. Concentrations of GSM and MIB were analyzed in the circulati…

kirjolohirecirculating aquaculture sytemlohikalatfood and beveragesGeoAMIB synthasemaku (aineen ominaisuudet)neoplasmsvesiviljely (kalatalous)digestive system diseasesoff-flavors
researchProduct

Desarrollo de la «Guía de consenso para el uso de medicamentos en insuficiencia renal»☆

2017

lcsh:R5-920SimvastatinConsensusbusiness.industry030503 health policy & servicesGeneral MedicineEzetimibe03 medical and health sciences0302 clinical medicineCartas al EditorHumansMedicineRenal Insufficiency030212 general & internal medicinelcsh:Medicine (General)0305 other medical scienceFamily PracticebusinessAtencion Primaria
researchProduct

All-Possible-Couplings Approach to Measuring Probabilistic Context

2013

From behavioral sciences to biology to quantum mechanics, one encounters situations where (i) a system outputs several random variables in response to several inputs, (ii) for each of these responses only some of the inputs may ‘‘directly’’ influence them, but (iii) other inputs provide a ‘‘context’’ for this response by influencing its probabilistic relations to other responses. These contextual influences are very different, say, in classical kinetic theory and in the entanglement paradigm of quantum mechanics, which are traditionally interpreted as representing different forms of physical determinism. One can mathematically construct systems with other types of contextuality, whether or …

mathematical parametersextended linear feasibility polytopekvanttimekaniikkasysteemibiologiatheorytodennäköisyysmatemaattinen analyysi
researchProduct

Treatment of B-CLL Cells with Bortezomib and Rituximab Reduces Cell Viability In Vitro..

2004

Introduction : In B-CLL, somatic mutation of IgVH genes defines a group of patients with favorable prognosis, whereas the absence of IgVH mutations is correlated with a worse outcome. Our previous data suggested that BCL-6 mutations identify a subgroup of patients with high risk of progression despite the presence of mutated IgVH gene, but the clinical significance of this molecular alteration remains uncertain. New approaches are now being tested for the treatment of B-CLL. Proteasome inhibitor, Bortezomib (Btz), and monoclonal antibodies specific for surface antigens, Rituximab (Rtx), represent potential therapeutic strategy. Objetives : To study the effects of Btz and Rtx on viability of…

medicine.diagnostic_testBortezomibLymphocyteImmunologyCell BiologyHematologyBiochemistryMolecular biologyFlow cytometrychemistry.chemical_compoundmedicine.anatomical_structurechemistryAntigenImmunologymedicineProteasome inhibitorDoubling timePropidium iodideViability assaymedicine.drugBlood
researchProduct

The effects of ezetimibe on LDL-cholesterol: quantitative or qualitative changes ?

2009

Ezetimibe represents the first of a new class of agents, the cholesterol absorption inhibitors, able to reduce low-density lipoproteins (LDL)-cholesterol by 15-25% from baseline in monotherapy and on top of statins and fibrates. To-date all the data regarding the efficacy of ezetimibe comes from the studies of its lipid-lowering power. Yet, recent findings from the ENHANCE study on atherosclerosis progression showed that the addition of ezetimibe to simvastatin in patients with heterozygous familial hypercholesterolemia did not affect the mean change in carotid intima-media thickness, although a significant reduction in LDL-cholesterol levels was present. Therefore, we cannot exclude that e…

medicine.medical_specialty10265 Clinic for Endocrinology and Diabetology610 Medicine & healthFamilial hypercholesterolemiaBioinformatics2705 Cardiology and Cardiovascular Medicinechemistry.chemical_compoundEzetimibePredictive Value of TestsInternal medicinemedicineAnimalsHumansProspective cohort studyCardiovascular risk Cholesterol LDL size Small dense LDLDyslipidemiasEzetimibe LDL-cholesterolCholesterolVascular diseasebusiness.industryAnticholesteremic AgentsHypertriglyceridemiaReproducibility of ResultsCholesterol LDLEzetimibemedicine.diseaseTreatment OutcomeEndocrinologychemistrySimvastatinAzetidinesDrug Therapy Combinationlipids (amino acids peptides and proteins)Hydroxymethylglutaryl-CoA Reductase InhibitorsCardiology and Cardiovascular MedicinebusinessBiomarkersDyslipidemiamedicine.drug
researchProduct

Choosing an ideal pharmacotherapeutic strategy for dyslipidemia in children.

2018

Dyslipdiemia can manifest at a young age, and it is a risk factor for atherosclerotic cardiovascular disease (ASCVD), the principal cause of mortality in developed nations. Therefore, treating it a...

medicine.medical_specialtyAdolescentFamilial hypercholesterolemiastatins03 medical and health sciences0302 clinical medicineEzetimibechildrenmedicinePharmacology (medical)Risk factorIntensive care medicinePharmacologyfamilial hypercholesterolemiaAtherosclerotic cardiovascular diseasebusiness.industryfungidyslipidemiafood and beveragesGeneral Medicinemedicine.diseaseYoung age030220 oncology & carcinogenesisbusinessDeveloped country030217 neurology & neurosurgeryDyslipidemiamedicine.drugezetimibeExpert opinion on pharmacotherapy
researchProduct

Future perspectives of the pharmacological management of diabetic dyslipidemia

2019

Introduction: Diabetic dyslipidemia is frequent among patients with type 2 diabetes mellitus (T2DM) and is characterized by an increase in triglycerides (TGs), low-density lipoprotein cholesterol (LDL-C), and small-dense (atherogenic) particles, and by a decrease in low high-density lipoprotein cholesterol (HDL-C) and apolipoprotein (Apo) A1 that are strongly related to insulin resistance. The increased flux of free fatty acids from adipose tissue to the liver aggravates hepatic insulin resistance and promotes all of aspects of the dyslipidemic state. Areas covered: Statins are the first-line agents for treatment while other lipid-lowering drugs (ezetimibe, fibrate and proprotein convertase…

medicine.medical_specialtyApolipoprotein Bmedicine.drug_classglucagon like peptide-1 receptor agonist (GLP-1RA)Fibrate030226 pharmacology & pharmacystatins03 medical and health sciences0302 clinical medicineInsulin resistanceEzetimibeInternal medicinemedicineHumansHypoglycemic AgentsPharmacology (medical)General Pharmacology Toxicology and PharmaceuticsOmega 3 fatty acidDyslipidemiasHypolipidemic Agentsfibratebiologybusiness.industrydyslipidemianutritional and metabolic diseasesType 2 Diabetes MellitusGeneral MedicineLipidmedicine.diseasesodium/glucose cotransporter 2 inhibitors (SGLT-2is)LipidsEndocrinologyDiabetes Mellitus Type 2Cardiovascular Diseases030220 oncology & carcinogenesisDipeptidyl peptidase-4 inhibitors (DPP-4is)Dietary Supplementsbiology.proteinKexinlipids (amino acids peptides and proteins)Hydroxymethylglutaryl-CoA Reductase InhibitorHydroxymethylglutaryl-CoA Reductase InhibitorsInsulin ResistancebusinessDyslipidemiamedicine.drugezetimibeproprotein convertase subtilisin/kexin type 9 (PCSK9)
researchProduct